-
公开(公告)号:US20130131090A1
公开(公告)日:2013-05-23
申请号:US13813318
申请日:2011-08-01
申请人: Bandi Parthasaradhi Reddy , Kura Rathnakar Reddy , Rapolu Raji Reddy , Dasari Muralidhara Reddy , Thungathurthy Srinivasa Rao , Bandi Vamsi Krishna
发明人: Bandi Parthasaradhi Reddy , Kura Rathnakar Reddy , Rapolu Raji Reddy , Dasari Muralidhara Reddy , Thungathurthy Srinivasa Rao , Bandi Vamsi Krishna
IPC分类号: C07D405/10
CPC分类号: C07D405/10 , C07D405/04
摘要: The present invention provides novel dioxalate salt of lapatinib, process for its preparation and pharmaceutical compositions comprising it. The present invention also provides novel monobesylate salt of lapatinib, process for its preparation and pharmaceutical compositions comprising it. The present invention further provides a process for the preparation of monohydrate form of lapatinib ditosylate. The present invention further provides a process for the preparation of anhydrous form of lapatinib ditosylate.
摘要翻译: 本发明提供了拉帕替尼的新型二油酸盐,其制备方法和包含其的药物组合物。 本发明还提供了拉帕替尼的新型单伯酯盐,其制备方法和包含其的药物组合物。 本发明进一步提供了制备拉帕替尼二磺酸一水合物形式的方法。 本发明还提供了制备无水形式的拉帕替尼二甲磺酸酯的方法。
-
公开(公告)号:US09150547B2
公开(公告)日:2015-10-06
申请号:US13989541
申请日:2011-11-11
申请人: Bandi Parthasaradhi Reddy , Kura Rathnakar Reddy , Dasari Muralidhara Reddy , Thungathurthy Srinivasa Rao , Bandi Vamsi Krishna
发明人: Bandi Parthasaradhi Reddy , Kura Rathnakar Reddy , Dasari Muralidhara Reddy , Thungathurthy Srinivasa Rao , Bandi Vamsi Krishna
IPC分类号: C07D403/12 , C07D239/42
CPC分类号: C07D403/12 , C07D239/42
摘要: The present invention provides a commercially viable process for preparing pazopanib and its pharmaceutically acceptable acid addition salts thereof in high yields using novel intermediate. The present invention also provides a process for the purification of pazopanib hydrochloride.
摘要翻译: 本发明提供了使用新型中间体以高产率制备比唑帕尼及其药学上可接受的酸加成盐的商业上可行的方法。 本发明还提供了盐酸帕唑帕尼的纯化方法。
-
公开(公告)号:US08703788B2
公开(公告)日:2014-04-22
申请号:US13989602
申请日:2011-11-11
申请人: Bandi Parthasaradhi Reddy , Kura Rathnakar Reddy , Dasari Muralidhara Reddy , Thungathurthy Srinivasa Rao , Bandi Vamsi Krishna
发明人: Bandi Parthasaradhi Reddy , Kura Rathnakar Reddy , Dasari Muralidhara Reddy , Thungathurthy Srinivasa Rao , Bandi Vamsi Krishna
IPC分类号: A01N43/54 , A61K31/505
CPC分类号: C07D401/14 , A61K31/506
摘要: The present invention provides a novel crystalline form of nilotinib hydrochloride, process for its preparation and pharmaceutical compositions comprising it.
摘要翻译: 本发明提供了盐酸尼洛替尼的新型结晶形式,其制备方法和包含其的药物组合物。
-
公开(公告)号:US09540406B2
公开(公告)日:2017-01-10
申请号:US14123290
申请日:2012-05-21
申请人: Bandi Parthasaradhi Reddy , Kura Rathnakar Reddy , Dasari Muralidhara Reddy , Thungathurthy Srinivasa Rao , Bandi Vamsi Krishna
发明人: Bandi Parthasaradhi Reddy , Kura Rathnakar Reddy , Dasari Muralidhara Reddy , Thungathurthy Srinivasa Rao , Bandi Vamsi Krishna
IPC分类号: C07F9/6558
CPC分类号: C07F9/65583
摘要: The present invention provides a novel process for reducing palladium content in fosaprepitant dimeglumine.
摘要翻译: 本发明提供了一种降低二甲氧基呋喃葡萄糖中钯含量的新方法。
-
公开(公告)号:US20140107337A1
公开(公告)日:2014-04-17
申请号:US14123290
申请日:2012-05-21
申请人: Bandi Parthasaradhi Reddy , Kura Rathnakar Reddy , Dasari Muralidhara Reddy , Thungathurthy Srinivasa Rao , Bandi Vamsi Krishna
发明人: Bandi Parthasaradhi Reddy , Kura Rathnakar Reddy , Dasari Muralidhara Reddy , Thungathurthy Srinivasa Rao , Bandi Vamsi Krishna
IPC分类号: C07F9/6558
CPC分类号: C07F9/65583
摘要: The present invention provides a novel process for reducing palladium content in fosaprepitant dimeglumine.
摘要翻译: 本发明提供了一种降低二甲氧基呋喃葡萄糖中钯含量的新方法。
-
6.
公开(公告)号:US20130245262A1
公开(公告)日:2013-09-19
申请号:US13989541
申请日:2011-11-11
申请人: Bandi Parthasaradhi Reddy , Kura Rathnakar Reddy , Dasari Muralidhara Reddy , Thungathurthy Srinivasa Rao , Bandi Vamsi Krishna
发明人: Bandi Parthasaradhi Reddy , Kura Rathnakar Reddy , Dasari Muralidhara Reddy , Thungathurthy Srinivasa Rao , Bandi Vamsi Krishna
IPC分类号: C07D403/12 , C07D239/42
CPC分类号: C07D403/12 , C07D239/42
摘要: The present invention provides a commercially viable process for preparing pazopanib and its pharmaceutically acceptable acid addition salts thereof in high yields using novel intermediate. The present invention also provides a process for the purification of pazopanib hydrochloride.
摘要翻译: 本发明提供了使用新型中间体以高产率制备比唑帕尼及其药学上可接受的酸加成盐的商业上可行的方法。 本发明还提供了盐酸帕唑帕尼的纯化方法。
-
公开(公告)号:US20130245052A1
公开(公告)日:2013-09-19
申请号:US13989602
申请日:2011-11-11
申请人: Bandi Parthasaradhi Reddy , Kura Rathnakar Reddy , Dasari Muralidhara Reddy , Thungathurthy Srinivasa Rao , Bandi Vamsi Krishna
发明人: Bandi Parthasaradhi Reddy , Kura Rathnakar Reddy , Dasari Muralidhara Reddy , Thungathurthy Srinivasa Rao , Bandi Vamsi Krishna
IPC分类号: C07D401/14
CPC分类号: C07D401/14 , A61K31/506
摘要: The present invention provides a novel crystalline form of nilotinib hydrochloride, process for its preparation and pharmaceutical compositions comprising it.
摘要翻译: 本发明提供了盐酸尼洛替尼的新型结晶形式,其制备方法和包含其的药物组合物。
-
公开(公告)号:US20130345418A1
公开(公告)日:2013-12-26
申请号:US13872373
申请日:2013-04-29
申请人: Bandi Parthasaradhi Reddy , Kura Rathnakar Reddy , Rapolu Raji Reddy , Dasari Muralidhara Reddy , Thungathurthy Srinivasa Rao
发明人: Bandi Parthasaradhi Reddy , Kura Rathnakar Reddy , Rapolu Raji Reddy , Dasari Muralidhara Reddy , Thungathurthy Srinivasa Rao
IPC分类号: C07D413/06
CPC分类号: C07D413/06
摘要: The present invention relates to a process for obtaining pure aprepitant substantially free of undesired diastereomeric isomer, namely 5-[2(S)-[1(RS)-[3,5-bis(trifluoromethyl)-phenypethoxy]-3-(S)-(4-fluorophenyl)-morpholin-4-yl-methyl]-3,4-dihydro-2H-1,2,4-triazol-3-one. The present invention further provides an improved process for preparation of aprepitant crystalline form II. The present invention also relates to novel amorphous form of aprepitant, a process for its preparation and to a pharmaceutical composition comprising it. The present invention further relates to aprepitant having a mean particle size of less than about 11.5 microns, a process for its preparation and to a pharmaceutical composition comprising it. Thus, for example, aprepitant having a content of diastereomeric impurity of 1.1% is dissolved in ethyl acetate at 70° C., the solution is concentrated to half the initial volume by distilling off ethyl acetate, and the resulting solid is collected at 0-5° C. to give pure aprepitant substantially free of its diastereomeric impurity.
摘要翻译: 本发明涉及一种获得基本上不含不期望的非对映体异构体的纯阿拉曲肽的方法,即5- [2(S) - [1(RS) - [3,5-双(三氟甲基) - 苯乙氧基] -3- ) - (4-氟苯基) - 吗啉-4-基 - 甲基] -3,4-二氢-2H-1,2,4-三唑-3-酮。 本发明进一步提供了制备阿瑞匹坦晶型II的改进方法。 本发明还涉及新型无定形形式的阿瑞匹坦,其制备方法和包含它的药物组合物。 本发明还涉及具有小于约11.5微米的平均粒度的阿瑞匹坦剂,其制备方法和包含其的药物组合物。 因此,例如,将具有1.1%非对映异构体杂质的阿瑞消制剂溶于70℃的乙酸乙酯中,通过蒸馏除去乙酸乙酯将溶液浓缩至初始体积的一半,并将所得固体在0- 5℃,得到基本上不含其非对映异构体杂质的纯制剂。
-
公开(公告)号:US08389531B2
公开(公告)日:2013-03-05
申请号:US11994613
申请日:2007-07-11
申请人: Bandi Parthasaradhi Reddy , Kura Rathnakar Reddy , Rapolu Raji Reddy , Dasari Muralidhara Reddy , Thungathurthy Srinivasa Rao
发明人: Bandi Parthasaradhi Reddy , Kura Rathnakar Reddy , Rapolu Raji Reddy , Dasari Muralidhara Reddy , Thungathurthy Srinivasa Rao
IPC分类号: A01N43/54 , A61K31/517 , C07D239/72
CPC分类号: C07D239/94
摘要: The present invention provides an improved and commercially viable process for preparation of erlotinib substantially free of N-methoxyethyl impurity, namely N-[(3-ethynylphenyl)-(2-methoxyethyl)]-6,7-bis(2-methoxyethoxy)-4-quinazolinamine, and its pharmaceutically acceptable acid addition salts thereof in high purity and in high yield. According to the present invention, erlotinib or a pharmaceutically acceptable acid addition salt of erlotinib substantially free of N-methoxyethyl impurity is prepared by isolating erlotinib or a pharmaceutically acceptable salt of erlotinib from a solvent medium comprising dimethyl sulfoxide and an alcoholic solvent.
摘要翻译: 本发明提供了一种改进的和商业可行的制备基本上不含N-甲氧基乙基杂质的厄洛替尼即N - [(3-乙炔基苯基) - (2-甲氧基乙基)] -6,7-双(2-甲氧基乙氧基) - 4-喹唑啉胺及其药学上可接受的酸加成盐,其纯度高,产率高。 根据本发明,通过从包含二甲基亚砜和醇溶剂的溶剂介质中分离厄洛替尼或埃洛替尼的药学上可接受的盐,来制备基本上不含N-甲氧基乙基杂质的厄洛替尼或其药学上可接受的厄洛替尼的酸加成盐。
-
公开(公告)号:US20110263865A1
公开(公告)日:2011-10-27
申请号:US13120449
申请日:2008-12-24
申请人: Bandi Parthasaradhi Reddy , Kura Rathnakar Reddy , Rapolu Raji Reddy , Dasari Muralidhara Reddy , Thungathurthy Srinivasa Rao
发明人: Bandi Parthasaradhi Reddy , Kura Rathnakar Reddy , Rapolu Raji Reddy , Dasari Muralidhara Reddy , Thungathurthy Srinivasa Rao
IPC分类号: C07D413/02
CPC分类号: C07D413/06
摘要: The present invention provides a novel isopropyl acetate solvate form of zolmitriptan, and a process for its preparation thereof. The present invention also provides a process for preparation of zolmitriptan polymorph A. Thus, for example, zolmitriptan isopropanol solvate was dissolved in isopropyl acetate at 25 deg C, the contents were heated to reflux for 30 minutes and the separated solid was filtered, washed with isopropyl acetate to give zolmitriptan isopropyl acetate solvate.
摘要翻译: 本发明提供了一种新型的醋酸异丙酯异丙酯异丙酯形式及其制备方法。 本发明还提供了制备佐米曲坦多晶型物A的方法。因此,例如,在25℃将唑来曲坦异丙醇溶剂合物溶解于乙酸异丙酯中,将内容物加热至回流30分钟,将分离的固体过滤,用 乙酸异丙酯,得到佐米曲坦丙酸乙酯溶剂化物。
-
-
-
-
-
-
-
-
-